Plain-English translation of NCT07295340 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
After you have surgery to remove liver cancer, doctors will test your removed tumor tissue with a new imaging technology called folate-targeted near-infrared carbon dots. This technology uses special fluorescent markers designed to highlight cancer cells so that doctors can see tumor boundaries and small cancers more clearly. The study compares how well this new imaging method works compared to the standard pathology examination.
During liver cancer surgery, it can be very difficult for doctors to see exactly where the cancer ends and healthy liver begins. The new imaging technology is designed to make these boundaries clearer and help doctors identify tiny cancer spots that might otherwise be missed, which could improve surgical outcomes.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will have your standard liver cancer surgery as planned. After your surgeon removes the tumor, the tissue sample will be treated with the new imaging dye and scanned using a special camera in the lab. Your removed tissue will then undergo standard pathology examination as usual. The entire additional imaging process happens on your tissue sample only and does not require any extra visits or procedures for you.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China
Sponsor
West China Hospital
Enrollment target
~20 participants
Started
January 2026
Primary completion
April 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jiwei Huang Professor
West China Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.